Seeking to develop better antibodies
Today's monoclonal antibodies (mAbs) were demonstrated to be effective for the treatment of IBD, but the disease is still not adequately addressed in many patients. Spyre's pipeline builds on the validated biology of first-generation antibodies with the goal of developing and bringing to market novel therapies that improve efficacy and convenience for IBD patients.
Together with our partners, we apply expertise in protein engineering across five key properties:
RATIONAL COMBINATIONS
At Spyre, we are advancing rational combinations of therapeutic antibody product candidates. Our pre-clinical and planned clinical studies aim to study the safety and efficacy of the following combinations of our next generation product candidates to target IBD:
- SPY120 program: combines product candidates SPY001 (α4β7) and SPY002 (TL1A).
- SPY130 program: combines SPY001 (α4β7) and SPY003 (IL-23).
- SPY230 program: combines SPY002 (TL1A) and SPY003 (IL-23).
We are pursuing combination studies for our next-generation monoclonal antibodies informed by recent findings from research on combination approaches with third-party products in IBD.*
*JNJ VEGA Study, Feagan, B. G. et al. Lancet Gastroenterol. Hepatol. 8, 307–320 (2023)
PRECISION IMMUNOLOGY APPROACHES TO PATIENT SELECTION
We are working to develop genetic- or biomarker-based patient selection approaches across our portfolio of therapeutics to help identify patients who may have higher likelihood of benefiting from our investigational products, if approved.
We are pursuing patient selection approaches informed by recent findings from research* showing promise in IBD:
